Healthy Skepticism Library item: 10326

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Tanne JH.
FDA calls for warnings on anaemia drugs amid reports of incentives to doctors.
BMJ 2007 May 19; 334:(7602):1022
http://www.bmj.com/cgi/content/full/334/7602/1022-a

Abstract:

The committee of the US Food and Drug Administration (FDA) that advises on oncology drugs last week recommended new warnings on erythropoiesis stimulating drugs that are given to patients undergoing chemotherapy to counteract anaemia. Patients undergoing dialysis are also often given the drugs.

The committee said that such synthetic erythropoietins (also called epoetins or “epo drugs”) were associated with an increased risk of cardiovascular events and possibly of progression of cancer. It unanimously recommended new clinical trials.

The FDA committee’s recommendations came only days after the New York Times published a story on its front page headlined “Doctors reaping millions for use of anemia drugs” (www.nytimes.com, 9 May) and the Wall Street Journal reported how Johnson & Johnson promoted epoetin alfa (www.wsj.com, 10 May “Suit details how J&J pushed sales of Procrit”).

In March the FDA called for a review of two drugs made by Amgen, . . .

Keywords:
Publication Types: News MeSH Terms: Anemia/drug therapy* Drug Labeling Hematinics/adverse effects* Humans Motivation United States United States Food and Drug Administration Substances: Hematinics